Key statistics
As of last trade Catalyst Pharmaceuticals Inc (CN2:DUS) traded at 18.12, -4.48% below its 52-week high of 18.97, set on Sep 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 17.69 |
---|---|
High | 18.12 |
Low | 17.66 |
Bid | 18.20 |
Offer | 18.28 |
Previous close | 17.98 |
Average volume | 277.78 |
---|---|
Shares outstanding | 118.69m |
Free float | 111.55m |
P/E (TTM) | 36.98 |
Market cap | 2.34bn USD |
EPS (TTM) | 0.5335 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 15:31 BST.
More ▼
Announcements
- Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
- Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
- Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
- Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
- Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
- Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
- Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
- Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
- Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
- Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
More ▼